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tCR  t cell receptor
tIL  tumour infiltrating lymphocyte
Introduction
the Cancer Society Symposium `Immunotherapy of Can-
cer—present Status and Future promise´ was held at a 
time when immunotherapy is experiencing a major break-
through in terms of clinical efficacy and proving its value 
as an important treatment modality for cancer. A number of 
highlights from recent findings were presented at the meet-
ing by a selection of international and national speakers. 
the symposium primarily focused on the following top-
ics: (1) adoptive cell therapy, (2) therapeutic vaccination, 
(3) cellular regulators in the tumour microenvironment, 
and (4) targeting immune-regulatory pathways. the Cancer 
Society Symposium was a small intensive meeting with an 
educational focus. It hosted 50 young scientists, many of 
whom were phD students who presented their own projects 
as a component of the poster session.
Adoptive cell therapy
Adoptive cell transfer immunotherapy (ACt) was pioneered 
by Steven A. Rosenberg and colleagues at the national Insti-
tutes of Health, USA, in the early 1990s. When autologous 
tumour infiltrating lymphocytes (tILs) were infused into 
patients with metastatic melanoma, this treatment resulted 
in unprecedented clinical responses. the original protocol, 
in some cases with minor modifications, was later extended 
to a handful of other centres, which achieved similar results 
in small single-institution phase I/II trials. two of these 
centres presented their recent findings at this Symposium. 
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ACt  Adoptive cell transfer immunotherapy
ALL  Acute lymphocytic leukaemia
CAF  Cancer-associated fibroblast
CAR  Chimeric antigen receptor
CAR19  Chimeric antigen receptors directed to CD19
CLL  Chronic lymphocytic leukaemia
COX-2  Cyclooxygenase-2
CR  Complete response
DC  Dendritic cell
HpV  Human papillomavirus
ID  Intradermally
IDO  Indoleamine-pyrrole 2,3-dioxygenase
IV  Intravenous
MDSC  Myeloid-derived suppressor cell
nSCLC  non-small cell lung cancer
pR  partial responses
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a series of Focussed Research Reviews based on lectures given  
at the conference.
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Inge Marie Svane (Herlev Hospital, Denmark) presented 
data from an ongoing phase I/II trial where tILs were 
infused in combination with IL-2 in low (2 MIU/day, sc. for 
14 days) or intermediate (“decrescendo-regimen”, 18 MU/
m2 over 6, 12, 18 and 24 h, followed by 4.5 MU/m2/day for 
3 days) doses. In the low-dose group of six patients, there 
was an overall response rate of 33 %, which represented two 
complete responders. In the intermediate-dose group (15 
patients), there was an overall response rate of 53 % (eight 
patients) with one complete responder. the data presented 
indicated that reduced doses of IL-2 could be used with-
out diminishing clinical efficacy. Because toxicities related 
to the administration of high-dose IL-2 have been a major 
challenge, which previously impaired broad application of 
these methods, these results can stimulate the initiation of 
ACt programs at other institutions.
Furthermore, Svane showed that upon recognition of an 
autologous tumour, IFn-γ/tnF-α-producing t cells were 
significantly correlated to clinical outcome. Indeed, this 
finding demonstrated that tumour reactivity is essential and 
that strategies to increase the fraction of tumour reactive t 
cells in the final product may have a clinical effect. Con-
sistent with this idea, pre-exposure of autologous tumours 
to IFn-γ increased overall t cell recognition by tIL prod-
ucts via an up-regulation of HLA molecules. thus, pre-
sensitisation of tumour lesions with interferons could serve 
as a valuable approach to increase tumour recognition, as 
presented in a poster session by Marco Donia (Herlev Hos-
pital, Denmark).
Combination therapies may additionally increase the 
tumour elimination mediated by adoptively transferred 
tILs, as was further alluded to by Patrick Hwu (MD 
Anderson Cancer Center, Houston, USA). His group is 
similarly performing adoptive cell therapy with mela-
noma tumour infiltrating lymphocytes, but they are also 
very actively investigating combination therapies, includ-
ing combination with BRAF inhibition, as this targeted 
therapy has been shown to increase tumour infiltration by 
t cells. Furthermore, a high-throughput screening plat-
form to identify compounds that most efficiently enhance 
the ability of tumour-specific t cells to kill autolo-
gous tumour and to identify transcripts associated with 
immune resistance in tumour cells were performed. On 
the basis of these screens, selected drug candidates could 
be identified for experimental validation of combinatorial 
therapy.
Carl June (University of pennsylvania, philadelphia, 
pA, USA) showed two different aspects of the potency of 
adoptively transferred gene-modified t cells. First, he dem-
onstrated the off-target reactivity of a MAge-A3-directed 
t cell receptor (tCR) towards the cardiac muscle protein 
titin, resulting in two cases of fatal cardiac toxicity. this 
finding clearly showed the overwhelming potency of 
t-cell-mediated toxicity and highlights the need for effi-
cient strategies to screen for cross-reactivity of tCRs.
the second and more encouraging results regarding 
gene-modified t cells described the use of chimeric anti-
gen receptors (CARs) directed to CD19 (CAR19). t cells 
expressing CAR19 have now been successfully transferred 
to several paediatric and adult patients with acute lympho-
cytic leukaemia (ALL) and chronic lymphocytic leukae-
mia (CLL). In ALL, 10 of 12 treated patients achieved a 
complete response after treatment, with most responses still 
persisting years after therapy. thus, the complete response 
rates were higher in ALL than in CLL, and in a few cases, 
CLL patients relapsed with a CD19-negative tumour.
Importantly, all patients undergoing CAR19 therapy 
experienced B cell aplasia and required supportive immu-
noglobulin treatment. Other significant toxicities included 
tumour lysis syndrome, cytokine release syndrome, and 
macrophage activation syndrome. CAR-t cells trafficking 
to the central nervous system were identified, providing a 
rationale for the treatment of primary brain tumours with 
gene-engineered t cells.
thus, these results illustrated that specific t cells under 
suitable circumstances are very efficient in killing target-
expressing cells. the selection of targets and the specific-
ity of the CAR or tCR in use are essential to avoid seri-
ous adverse events, and for more heterogeneous tumours, 
simultaneous targeting of several molecules is needed to 
avoid target-negative escape mutants.
Therapeutic vaccination
therapeutic vaccination in cancer has long struggled 
to induce clinical efficacy and to correlate the induced 
immune reactivity against vaccine antigens to clini-
cal efficacy. A recent study from Immatics Biotechnolo-
gies gmbH, tübingen, germany, presented by Harpreet 
Singh, elegantly showed that both of these challenges 
could be overcome. He presented data from a phase I study 
and a subsequent phase II study with renal cell carcinoma 
patients receiving a therapeutic vaccination against multi-
ple tumour-associated peptides. these peptides were iden-
tified based on the MHC-associated presentation on renal 
cell carcinoma tissues when compared to healthy tissue. 
Interestingly, the data suggested an important role for pre-
conditioning with cyclophosphamide (300 mg/m2, single 
infusion) to induce clinically relevant immune responses 
because the preconditioned treatment group with one or 
more immune responses showed better survival than those 
that were not preconditioned; however, they harboured 
the same number of immune responses. the number of 
regulatory t cells was decreased following cyclophospha-
mide treatment. Furthermore, overall survival appeared to 
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be associated with a low number of circulating myeloid-
derived suppressor cells (MDSCs) and high serum concen-
trations of CCL17 and ApOA1, in which the latter of the 
two was particularly evident in combination with cyclo-
phosphamide. Immatics is currently working towards the 
generation of personalised vaccines, with a selection from 
“off-the-shelf” peptides based on the immunogenicity and 
tumour expression determined on a patient-specific basis.
Several other examples showed that peptide vaccina-
tion might also be effective in a therapeutic setting. Most 
evidently, this was demonstrated in high-grade human 
papillomavirus (HpV)-positive vulvar intraepithelial neo-
plasia with a clinical outcome associated with lesion size 
at entry, and the induction of a strong vaccine prompted 
HpV-specific immune response and the absence of a 
vaccine-induced regulatory response. At the symposium, 
Sjoerd van der Burg (Leiden University Medical Cen-
tre, the netherlands) presented data from a recent phase 
II clinical trial involving 20 patients with HpV16-positive 
recurrent cervical cancer. the vaccine, which consisted of 
long overlapping peptides covering the entire sequence of 
e6 and e7 onco-proteins, administered in Montanide ISA-
51, failed to induce a clinical response with an effect on 
overall survival. However, among the vaccinated patients, 
the long-term survivors (patients surviving longer than the 
median overall survival rate of 12.6 months) stimulated a 
better immune response to vaccination than the short-term 
survivors (patients surviving less than 12.6 months), when 
measured based on HpV16-specific proliferation or IFn-
γ eLISpOt. these HpV-targeting vaccines also served to 
pioneer long-peptide vaccinations, a strategy that was also 
applied by Gustav Gaudernack (Oslo University Hospi-
tal, norway), as a means to stimulate immune responses 
against hteRt. they observed that longer survival corre-
lated with epitope spreading, including more than two pep-
tides from hteRt.
Graham Pawelec (University of tübingen, germany) 
suggested that the mechanism behind epitope spreading 
could be related to the in vitro functionality of antigen-
specific t cells, which correlated with long-term survival of 
late-stage melanoma patients. thus, the presence of circu-
lating nY-eSO-1- or Melan-A-responsive t cells was cor-
related with prolonged survival, but this was counteracted 
by a high level of circulating MDSCs. Furthermore, for 
Melan-A but not nY-eSO-1 responses, a negative effect of 
CD4 t cell reactivity was observed when these cells pro-
duced either IL-4 or IL-17, which potentially represent a 
non-classical form of regulatory t cell.
Another major component in therapeutic vaccination 
consists of dendritic cell-based vaccinations. Dendritic 
cells (DCs), which are major players in the initiation of 
an immune response, have been extensively explored as 
vaccine candidates. their source of origin and in vitro 
maturation methods used have resulted in a large variety 
of DCs being used in clinical trials, but there is still no 
consensus as to what is the best DC type for vaccination 
purposes. Kris Thielemans (Free University of Brussels, 
Belgium) has pioneered the use of RnA-electroporated 
DCs for vaccine purposes. Immature monocyte-derived 
DCs were electroporated with mRnA encoding CD40L, 
CD70, and catLR4 (triMix mRnA). In a clinical trial 
with 35 advanced melanoma patients, the DCs were also 
electroporated with gp100, tyrosinase, MAge-C2, or 
MAge-A3 mRnA encoded as a fusion with HLA class 
II targeting signal of DC-LAMp (triMixDC-MeL). this 
DC-based vaccine was administered either intradermally 
(ID) or combined ID with intravenous (IV) administration. 
these results indicated that combined IV/ID administra-
tion increased clinical efficacy, with two partial responses 
(pR) and two complete responses (CR) observed out of 15 
patients in this cohort. the group further tested the use of 
triMixDC-MeL in combination with ipilimumab treat-
ment. Here, five CR and five pR were observed among 35 
evaluable patients, demonstrating that such combinations 
may increase the clinical responses observed with either 
therapy alone.
Glenn Dranoff (Dana Farber Cancer Institute, Boston, 
USA) elegantly showed how a proinflammatory microen-
vironment might drive lung cancer pathogenesis. Subse-
quently, he showed his recent results on the use of autolo-
gous melanoma cells engineered to secrete gM-CSF as 
the main vaccine component, administered with or without 
anti-CtLA4 antibodies. He observed that the ratio of CD8 
t cells to Foxp3-positive regulatory t cell correlated to 
tumour regression, which suggested that this balance might 
be further skewed to increase a clinical response. In-depth 
analyses of patients with clinical benefits from this therapy 
and evaluation in experimental mouse models have led to 
a target discovery program, identifying factors associated 
with immune-mediated tumour destruction. In addition, 
he showed how t cell-targeted immunotherapy can effi-
ciently trigger a potent humoral response that modulates 
the dynamics of the tumour microenvironment.
Cellular regulators in the tumour microenvironment
Infiltration of t cells in human tumours may have great 
prognostic value, as demonstrated most significantly in 
colorectal cancer via the mapping of immune involvement, 
as pioneered by Jérôme Galon (InSeRM, paris, France). 
In a large interdisciplinary effort, he described the effect 
of various immune cell infiltrates, numbers, location, and 
interaction in correlation with clinical outcome. galon 
and colleagues analysed the immune landscape of colo-
rectal cancer in correlation with progression-free survival. 
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they determined cell types associated with good clinical 
outcome (e.g. CD3, CD20, CD8, CD45RO) when present 
either at the invasive margin or at the centre of the tumour. 
Other cell types have a negative effect on survival, e.g. 
IL-17-producing cells, and, interestingly, this is primarily 
evident when they are located at the invasive margin. Fur-
thermore, the group reported the interplay between all of 
the investigated cell types and specifically emphasised the 
role of the B cell component and its correlation with high 
expression of CXCL13 (B cell chemoattractant), CD20, 
and IL-21 with a favourable clinical outcome.
A simplified description of the immune infiltrate, the 
immunoscore, has been shown to outrank the tnM classi-
fication in terms of prognostic value. the prognostic value 
of the immunoscore is currently being evaluated at several 
independent centres.
One mechanism by which tumours modify immune 
infiltration and immune function is via altered myelopoie-
sis, which causes an accumulation of immune-suppressive 
cells. Factors regulating this accumulation have been stud-
ied by Vincenzo Bronte (University of Verona, Italy) and 
colleagues. Bronte presented data at the symposium dem-
onstrating that down-regulation of microRnA miR-142-3p 
promoted the differentiation of bone marrow cells into 
M2-type macrophages. Furthermore, miR-142-3p affects 
IL6-mediated promotion of macrophage generation. Iden-
tification and targeting of such mechanisms responsible for 
the induction of the immune-suppressive tumour micro-
environment may improve the efficacy of cancer immune 
therapy.
In addition, microRnAs of the miR200 family are also 
involved in regulating cancer-associated fibroblasts (CAFs) 
and macrophages of the M2 phenotype, as presented by 
Pedro Barcellos-de-Souza (University of Florence, Italy). 
CAFs and M2 macrophages have been demonstrated to 
exhibit strong immune-suppressive capabilities, which play 
a crucial role in tumour progression.
In general, microRnAs appear to play an important role 
in the immunosuppressive microenvironment, and in the 
immunosuppressive phenotype of many cancer cells. Can-
cer cells often escape immune attack via a down-regulation 
of HLA or changes in the antigen-processing machinery. 
these defects may be driven either by structural alterations 
or by deregulation. Barbara Seliger (University of Halle, 
germany) described how these processes are similarly 
regulated by microRnA. thus, identification of regulatory 
miRs may provide both prognostic and therapeutic value.
Another subgroup of immune-suppressive cells, 
MDSCs, has been shown to display a strong inhibition of 
t cell-mediated antitumour activities via the production 
of nitric oxide and arginase. As shown by Viktor Uman-
sky (DKFZ, Heidelberg, germany), this cell type may 
be targeted through ultralow (non-cytotoxic) doses of 
chemotherapy, a strategy that can easily be implemented in 
combination with various immune therapeutic treatments.
One mechanism by which MDSC-like cells are induced 
in the tumour microenvironment was presented by Rolf 
Kiessling (Karolinska Institute, Stockholm, Sweden). He 
showed that melanoma cells may instruct CD14-positive 
monocytes to become MDSC-like cells with potent t cell 
inhibition properties. this conversion was dependent on 
cyclooxygenase-2 (COX-2) production and activation of 
the StAt-3 signalling pathway. this mechanism provides 
targets for alleviating the t cell suppression in the tumour 
microenvironment.
Targeting immune-regulatory pathways
Mechanisms of tumour-induced immune suppression/igno-
rance may be divided into two categories, as shown by 
analyses of melanoma metastases presented by Thomas F. 
Gajewski (University of Chicago, USA). Some patients/
lesions demonstrate an inflamed phenotype characterised 
by t cell infiltration that is functionally impaired through 
pD-L1, indoleamine-pyrrole 2,3-dioxygenase (IDO) and 
treg interactions and associated with t cell anergy. Other 
patients/lesions display a non-inflamed phenotype, which 
is characterised by a lack of t cell infiltration. the mecha-
nism underlying the non-inflamed phenotype is still incom-
pletely understood, but it is correlated with the lack of 
innate immune signalling, the absence of a type I IFn sig-
nature, and low chemokine production. In addition, tumour-
derived vascular endothelial cells are most likely distinct, 
as evidenced by the differential expression of the endothe-
lin B receptor. As many non-inflamed lesions showed high 
arginase expression, MDSCs might be a component associ-
ated with t cell exclusion. these differential mechanisms 
are clinically important. In patients with t cell infiltration, 
pD-L1, IDO, and tregs are largely seen as counteractive 
mechanisms for antitumour immune responses, and these 
patients are more likely to respond to CtLA-4, pD1/pD-
L1 or IDO blockade therapy. Other strategies should be 
explored in patients with a non-inflamed phenotype to 
initiate innate immune activation and to promote endog-
enous t cell priming and recruitment into the tumour 
microenvironment.
therapeutic targeting of immune-regulatory mecha-
nisms has already initiated a new era for immune therapy 
for cancer. evidently, patients can be cured by halting their 
intrinsic immune inhibitory pathways. thus, spontaneous 
antitumour immune responses have the ability to eradicate 
a growing tumour when the tumour-induced inhibitory 
mechanisms are abolished. this has clearly been demon-
strated through the clinical implementation of anti-CtLA4 
and anti-pD1 antibodies. Recent data from a clinical 
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evaluation of these compounds were presented by Antoni 
Ribas (UCLA, Los Angeles, USA). Impressive clinical 
responses were observed with pD1 and CtLA-4 blockade, 
which presented objective response rates of 38 and 11 %, 
respectively. the combination of these two agents dis-
played an objective response rate of 53 % in a phase I trial, 
including 53 patients who received concurrent therapy with 
nivolumab and ipilimumab and 33 patients who received 
sequenced treatment, which enhanced enthusiasm in the 
field to investigate combinatorial therapy.
A potential source for combinatorial therapy is BRAF-
targeted therapy. Inhibition of mutated BRAF via vemu-
rafenib results in significant clinical responses; however, 
the duration is usually limited. Molecular characterisa-
tion of the drug-related effects on signalling pathways has 
revealed a paradoxical effect in BRAF wild-type cells, 
resulting in the activation of the MApK signalling path-
way. this activation results in increased in vivo cytotoxic 
activity and intratumoural cytokine secretion by adoptively 
transferred t cells when combined with BRAF inhibition. 
this further resulted in superior antitumour reactivity when 
combinatorial therapy was investigated in immunocom-
petent mice. As more targeted therapies are emerging, the 
field for combining targeted therapies with immunothera-
pies will likely rapidly expand. these combinations may 
enhance immunotherapy without the potential risk of t cell 
killing, which forms an intrinsic threat for combinations 
with chemotherapy.
An alternative strategy for targeting inhibitory pathways 
is the capacity of the immune system to strike back on most 
regulatory circuits. It has been described and was presented 
by Mads Hald Andersen (Herlev University Hospital, 
Denmark) that cytotoxic t cells against immune inhibi-
tory molecules, such as IDO, pD-L1 and Foxp3, exist and 
may be enhanced in combination with other tumour-asso-
ciated antigens to increase tumour cell killing. this strat-
egy is ideal for combinations with therapeutic vaccination, 
and it was recently demonstrated in a small phase I study 
with IDO peptide vaccination of 15 HLA-A2-positive stage 
II–IV non-small cell lung cancer (nSCLC) patients that 
vaccination against IDO may support long-lasting disease 
stabilisation.
Final remarks
On the basis of the data presented during this meeting, the 
future for cancer immunotherapy looks very promising—
numerous new strategies and combination therapies are 
emerging, and the number of clinical trials within this field 
is rapidly evolving. through in-depth molecular charac-
terisation of these clinical initiatives, we will likely gain 
knowledge of the molecular mechanisms and signatures 
that are predictive for treatment outcome and provide a 
basis for rational design and patient selection to increase 
response rates.
this meeting provided an exceptional opportunity for 
young scientists approaching the field of cancer immuno-
therapy to interact with established leaders who presented 
their most recent works in an informal and stimulating 
environment. Compelling Q&A sessions extended dis-
cussions on recent results, initiated enthusiastic debates 
between speakers and students regarding the future of 
immunotherapy and generated novel ideas, which antici-
pate the next steps forward towards a cure for patients 
affected by metastatic malignancies.
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